Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Aug;87(8):593-603.
doi: 10.1097/OPX.0b013e3181e61bad.

Vision therapy/orthoptics for symptomatic convergence insufficiency in children: treatment kinetics

Mitchell Scheiman  1 , Marjean Taylor Kulp, Susan Cotter, G Lynn Mitchell, Michael Gallaway, Mark Boas, Rachel Coulter, Kristine Hopkins, Susanna Tamkins; Convergence Insufficiency Treatment Trial Study Group
Collaborators, Affiliations
Randomized Controlled Trial

Vision therapy/orthoptics for symptomatic convergence insufficiency in children: treatment kinetics

Mitchell Scheiman et al. Optom Vis Sci. 2010 Aug.

Abstract

Purpose: To evaluate the kinetics of change in symptoms and signs of convergence insufficiency (CI) during 12 weeks of treatment with commonly prescribed vision therapy/orthoptic treatment regimens.

Methods: In a randomized clinical trial, 221 children aged 9 to 17 years with symptomatic CI were assigned to home-based pencil push-ups (HBPP), home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+), office-based vergence/accommodative therapy with home reinforcement (OBVAT), or office-based placebo therapy with home reinforcement (OBPT). Symptoms and signs were measured after 4, 8, and 12 weeks of treatment. The outcome measures were the mean CI Symptom Survey (CISS), near point of convergence (NPC), positive fusional vergence (PFV), and proportions of patients who were classified as successful or improved based on a composite measure of CISS, NPC, and PFV.

Results: Only the OBVAT group showed significant improvements in symptoms between each visit (p < 0.001). Between weeks 8 and 12, all groups showed a significant improvement in symptoms. Between-group differences were apparent by week 8 (p = 0.037) with the fewest symptoms in the OBVAT group. For each group, the greatest improvements in NPC and PFV were achieved during the first 4 weeks. Differences between groups became apparent by week 4 (p < 0.001), with the greatest improvements in NPC and PFV in the OBVAT group. Only the OBVAT group continued to show significant improvements in PFV at weeks 8 and 12. The percentage of patients classified as "successful" or "improved" based on our composite measure increased in all groups at each visit.

Conclusions: The rate of improvement is more rapid for clinical signs (NPC and PFV) than for symptoms in children undergoing treatment for CI. OBVAT results in a more rapid improvement in symptoms, NPC and PFV, and a greater percentage of patients reaching pre-determined criteria of success when compared with HBPP, HBCVAT+, or OBPT.

Trial registration: ClinicalTrials.gov NCT00338611.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Convergence Insufficiency Symptom Survey: Mean at each study visit (A) and Mean change between visits (B).
Figure 2
Figure 2
Near point of convergence: Mean at each study visit (A) and Mean change between visits (B).
Figure 3
Figure 3
Positive fusional vergence break: Mean at each study visit (A) and Mean change between visits (B).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Convergence Insufficiency Treatment Trial Investigator Group. Randomized clinical trial of treatments for symptomatic convergence insufficiency in children. Arch Ophthalmol. 2008;126:1336–1349. - PMC - PubMed
    1. Convergence Insufficiency Treatment Trial Investigator Group. The convergence insufficiency treatment trial: design, methods, and baseline data. Ophthalmic Epidemiol. 2008;15:24–36. - PMC - PubMed
    1. Sheard C. Zones of ocular comfort. Am J Optom. 1930;7:9–25.
    1. Rouse M, Borsting E, Mitchell GL, Cotter SA, Kulp M, Scheiman M, Barnhardt C, Bade A, Yamada T. Validity of the convergence insufficiency symptom survey: a confirmatory study. Optom Vis Sci. 2009;86:357–363. - PMC - PubMed
    1. Borsting EJ, Rouse MW, Mitchell GL, Scheiman M, Cotter SA, Cooper J, Kulp MT, London R. Validity and reliability of the revised convergence insufficiency symptom survey in children aged 9 to 18 years. Optom Vis Sci. 2003;80:832–838. - PubMed

Publication types

Associated data